1.Perioperative Anticoagulation in Patients with Mechanical Heart Valves Undergoing Elective Surgery: Results of a Survey Conducted among Korean Physicians.
Doyeun OH ; Sehyun KIM ; Chang Young LIM ; Jong Seok LEE ; Seonyang PARK ; David GARCIA ; Mark A CROWTHER ; Walter AGENO
Yonsei Medical Journal 2005;46(1):66-72
The optimal perioperative anticoagulation management in patients on warfarin therapy is poorly defined due to the lack of randomized trials. Because guidelines are heterogeneous, it was hypothesized that "treatment strategies are not uniform in clinical practice". Between February 2003 and May 2003, a questionnaire with 4 different clinical scenarios was distributed to physicians by e-mail, or direct contact was made by a survey monitor. Two scenarios described the cases of patients with a mechanical heart valve (MHV) in the mitral position, with additional risk factors for a systemic embolism; one undergoing major (scenario 1) and the other minor surgery (scenario 3). Two scenarios described patients with an aortic MHV; one undergoing major (scenario 2) and the other minor (scenario 4) surgery. Different preoperative and postoperative management options were offered. The treatment options for all scenarios were the same. Of the 90 questionnaires distributed, 52 (57.8%) were returned. Hospitalization for full-dose intravenous unfractionated heparin (IV UH) was the most commonly selected strategy in the preoperative phase for scenarios 1 (59%), 2 (42%) and 3 (44%). In scenario 4, 34% chose IV UH. Outpatient, full- dose, subcutaneous UH or low-molecular-weight heparin (LMWH) was the most selected option in the postoperative phase for all scenarios, with the exception of number 4 (52.9% in scenario 1, 34% in scenario 2, 32%, in scenario 3 and 28% in scenario 4). Even among expert clinicians, the management of perioperative anticoagulation is heterogeneous. In particular, the definition of risk categories and the optimal intensity of antithrombotic drugs need to be defined by well-designed prospective studies.
Anticoagulants/*therapeutic use
;
Health Care Surveys
;
*Heart Valve Prosthesis
;
Humans
;
Korea/epidemiology
;
Perioperative Care/*methods
;
*Physicians
;
Risk Factors
;
Thrombosis/epidemiology/*prevention & control
;
Warfarin/*therapeutic use
2.Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients.
Zhan GAO ; Yue-jin YANG ; Bo XU ; Ji-lin CHEN ; Shu-bin QIAO ; Min YAO ; Jue CHEN ; Yong-jian WU ; Hai-bo LIU ; Jun DAI ; Jin-qing YUAN ; Jian-jun LI ; Run-lin GAO
Chinese Medical Journal 2008;121(6):513-517
BACKGROUNDWith the advent of drug-eluting stents (DES) and much lower rates of target vessel revascularization (TVR), whether adjunctive balloon postdilatation can further optimize outcome is still unknown. The present study was to compare the outcomes of postdilatation with un-postdilatation following deployment of DES.
METHODSFrom April 2004 to September 2006, 6479 consecutive Chinese patients who underwent DES implantation, including 1769 with postdilatation (1454 male, (57.9+/-10.8) years old) and 4710 without postdilatation (3819 male, (57.9+/-10.6) years old) were analyzed. Clinical and angiographic follow-up was performed at 7 months.
RESULTSCompared with the un-postdilatation group, the postdilatation group had more complex lesions and larger relevant vessel diameter (RVD). In the postdilatation group, in-stent residual restenosis was significantly improved right after the procedure ((16.80+/-5.88)% vs (19.60+/-6.07)%; P=0.000). There was no statistical difference in the major adverse cardiac events (MACE) rate between the groups (2.9% vs 3.3%; P=0.420), and there were also no statistical differences in death, acute myocardial infarction (AMI) and target lesion revascularization (TLR) rates in the two groups (0.1% vs 0.4%, P=0.127; 1.7% vs 1.3%, P=0.229; and 1.5% vs 2.0%, P=0.206, respectively). The in-stent thrombosis rate was almost the same in both groups (0.5% vs 0.5%; P=1.000). Seven months angiographic follow-up results showed that both in-stent and in-segment restenosis rates were lower in the postdilatation group (8.8% vs 15.6%, P=0.000; and 10.5% vs 17.3%, P=0.000), and so were in-stent and in-segment late loss ((0.32+/-0.12) mm vs (0.49+/-0.13) mm, P=0.000; and (0.24+/-0.08) mm vs (0.36+/-0.09) mm, P=0.001).
CONCLUSIONPostdilatation after DES deployment was safe and could reduce the restenosis rate, especially for more complex lesions.
Adult ; Aged ; Angioplasty, Balloon, Coronary ; Coronary Angiography ; Coronary Restenosis ; prevention & control ; Drug-Eluting Stents ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Thrombosis ; epidemiology
3.Deep Vein Thrombosis in the Lower Extremities in Comatose Elderly Patients with Acute Neurological Diseases.
Shoko Merrit YAMADA ; Yusuke TOMITA ; Hideki MURAKAMI ; Makoto NAKANE
Yonsei Medical Journal 2016;57(2):388-392
PURPOSE: Comatose elderly patients with acute neurological illness have a great risk of deep vein thrombosis (DVT). In this study, the incidence of DVT and the effectiveness of early initiation of treatment were evaluated in those patients. MATERIALS AND METHODS: Total 323 patients were admitted to our ward due to neurological diseases in one year, and 43 patients, whose Glasgow Coma Scale was < or =11 and who was older than > or =60 years, were included in this study. D-dimer was measured on admission and day 7, and lower-extremity ultrasonography was performed on day 7. When DVT was positive, heparin treatment was initiated, and further evaluation of pulmonary embolism (PE) was conducted. Vena cava filter protection was inserted in PE-positive patients. Incidence of DVT and PE, alteration of D-dimer value, and effect of heparin treatment were analyzed. RESULTS: DVT was positive in 19 (44.2%) patients, and PE was in 4 (9.3%). D-dimer was significantly higher in DVT-positive group on day 7 (p<0.01). No DVT were identified in patients with ischemic disease, while 66.7% of intracerebral hemorrhage and 53.3% of brain contusion patients were DVT positive. Surgery was a definite risk factor for DVT, with an odds ratio of 5.25. DVT and PE disappeared by treatment in all cases, and no patients were succumbed to the thrombosis. CONCLUSION: Patients with hemorrhagic diseases or who undergo operation possess high risk of DVT, and initiation of heparin treatment in 7 days after admission is an effective prophylaxis for DVT in comatose elderly patients without causing bleeding.
Acute Disease
;
Aged
;
Anticoagulants/adverse effects/therapeutic use
;
Antifibrinolytic Agents/therapeutic use
;
*Coma
;
Female
;
Fibrin Fibrinogen Degradation Products/therapeutic use
;
Hemorrhage/*epidemiology
;
Heparin/adverse effects/therapeutic use
;
Humans
;
Incidence
;
Japan/epidemiology
;
Lower Extremity
;
Male
;
Middle Aged
;
Nervous System Diseases/epidemiology
;
Neurosurgical Procedures/*adverse effects
;
Pulmonary Embolism/*complications/epidemiology/prevention & control
;
Risk Factors
;
Venous Thrombosis/epidemiology/*etiology/prevention & control
4.Anti-Heparin-Platelet Factor 4 Antibody is a Risk Factor for Vascular Access Obstruction in Patients Undergoing Hemodialysis.
Eun Young LEE ; Kyu Yoon HWANG ; Jong Oh YANG ; Sae Yong HONG
Journal of Korean Medical Science 2003;18(1):69-72
Since heparin is an anticoagulant commonly used in hemodialysis and the patients on hemodialysis are repeatedly exposed to heparin, heparin may be the cause of the development of heparin-dependent antibodies and thrombotic complications in patients on hemodialysis. The purpose of this study was to determine the prevalence and the clinical significance of the antibodies against heparin-platelet factor 4 complexes as determined by enzyme immunoassay in patients on maintenance hemodialysis. The prevalence of anti-heparin-platelet factor 4 antibodies was higher in hemodialysis patients than in normal subjects (8.8 vs 0.0%, p<0.05). The number of past episodes of vascular access obstruction per year was significantly higher in the anti-heparin-platelet factor 4 antibody positive group than antibody negative group. Anti-heparin-platelet factor 4 antibody positive patients experienced more frequent vascular access obstructions than control subjects. In conclusion, anti-heparin-platelet factor 4 antibody might be a risk factor for vascular access obstructions in patients with end-stage renal disease on maintenance hemodialysis.
Adult
;
Autoantibodies/immunology*
;
Autoimmune Diseases/immunology*
;
Catheters, Indwelling*
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Heparin/immunology*
;
Human
;
Kidney Failure, Chronic/blood
;
Kidney Failure, Chronic/immunology
;
Kidney Failure, Chronic/therapy*
;
Male
;
Middle Aged
;
Platelet Factor 4/immunology*
;
Recurrence
;
Renal Dialysis*
;
Risk Factors
;
Thrombophilia/immunology*
;
Thrombosis/epidemiology*
;
Thrombosis/immunology
;
Thrombosis/prevention & control
5.Prophylaxis against venous thromboembolism in orthopedic surgery.
Chinese Journal of Traumatology 2006;9(4):249-256
Venous thromboembolism (VTE), which is manifested as deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant cause of death, disability, and discomfort. They are frequent complications of various surgical procedures. The aging population and the survival of more severely injured patients may suggest an increasing risk of thromboembolism in the trauma patients. Expanded understanding of the population at risk challenges physicians to carefully examine risk factors for VTE to identify high-risk patients who can benefit from prophylaxis. An accurate knowledge of evidence-based risk factors is important in predicting and preventing postoperative DVT, and can be incorporated into a decision support system for appropriate thromboprophylaxis use. Standard use of DVT prophylaxis in a high-risk trauma population leads to a low incidence of DVT. The incidence of VTE is common in Asia. The evaluation includes laboratory tests, Doppler test and phlebography. Screening Doppler sonography should be performed for surveillance on all critically injured patients to identify DVT. D-Dimer is a useful marker to monitor prophylaxis in trauma surgery patients. The optimal time to start prophylaxis is between 2 hours before and 10 hours after surgery, but the risk of PE continues for several weeks. Thromboprophylaxis includes graduated compression stockings and anticoagulants for prophylaxis. Anticoagulants include Warfarin, which belongs to Vitamin K antagonists, unfractionated heparin, low molecular weight heparins, factor Xa indirect inhibitor Fondaparinux, and the oral IIa inhibitor Melagatran and ximelagatran. Recombinant human soluble thrombomodulin is a new and highly effective antithrombotic agent. Prophylactic placement of vena caval filters in selected trauma patients may decrease the incidence of PE. The indications for prophylactic inferior vena cava filter insertion include prolonged immobilization with multiple injuries, closed head injury, pelvic fracture, spine fracture, multiple long bone fracture, and attending discretion. Multiple-trauma patients are at increased risk for DVT but are also at increased risk of bleeding, and the use of heparin may be contraindicated. Serial compression devices (SCDs) are an alternative for DVT prophylaxis. Compression devices provide adequate DVT prophylaxis with a low failure rate and no device-related complications. Immobilization is one of important reasons of VTE. The ambulant patient is far less likely to develop complications of inactivity, not only venous thrombosis, but also contractures, decubitus ulcers, or osteoporosis (with its associated fatigue fractures), as well as bowel or bladder complications.
Anticoagulants
;
therapeutic use
;
Factor Xa Inhibitors
;
Heparin
;
therapeutic use
;
Heparin, Low-Molecular-Weight
;
therapeutic use
;
Humans
;
Orthopedic Procedures
;
adverse effects
;
Postoperative Complications
;
epidemiology
;
Pulmonary Embolism
;
prevention & control
;
Recombinant Proteins
;
therapeutic use
;
Risk Factors
;
Thrombomodulin
;
therapeutic use
;
Vena Cava Filters
;
Venous Thrombosis
;
epidemiology
;
prevention & control
;
Vitamin K
;
antagonists & inhibitors
;
Warfarin
;
therapeutic use
6.How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?.
Jun Hyung KIM ; Young Bin SONG ; Dae Hee SHIN ; Je Sang KIM ; Jin Oh CHOI ; Young Kun ON ; June Soo KIM
Yonsei Medical Journal 2009;50(1):83-88
PURPOSE: Although warfarin is an effective oral anticoagulation (OAC) drug to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation (NVAF), long term follow-up data are scarce to be certain whether the target INR level is maintained in warfarin-treated patients in Korea. The aim of this study was to evaluate how well INRs are maintained within the target range using a new index, INR stability (= 100 x number of INRs within target range/total number of INR measurements) which we made, and to find out any correlation between thromboembolic events and INR stability. MATERIALS AND METHODS: This study was an observational analysis of retrospectively collected data of 129 patients with NVAF from April 2000 to December 2005 at a single tertiary hospital. All patients were registered at the anticoagulation service. RESULTS: The median duration of follow up was 2.03 years (interquartile range 1.35 - 2.96). During the follow-up period, 60.9 +/- 14.9% of the INR were within the target INR range. INR stability was not significantly different between patients without and with stroke (61.2 +/- 15.0% vs 53.3 +/- 4.9%). Among the known factors affecting fluctuations of the INR value, the most frequent factor was noncompliance (41.8%). CONCLUSION: The present study showed that it was not enough to maintain INR values within the target range in warfarin-treated patients with NVAF even at a tertiary hospital. Noncompliance is an important problem which interferes with maintaining target INR range.
Adult
;
Age Factors
;
Aged
;
Aged, 80 and over
;
Anticoagulants/*therapeutic use
;
Atrial Fibrillation/*drug therapy/epidemiology/etiology
;
Drug Monitoring/methods
;
Female
;
Follow-Up Studies
;
Heart Valves
;
Humans
;
*International Normalized Ratio
;
Male
;
Middle Aged
;
Patient Compliance
;
Retrospective Studies
;
Risk Factors
;
Thrombosis/*blood/epidemiology/*prevention & control
;
Warfarin/*therapeutic use
7.A Singapore perspective on the use of a short course of chemothromboprophylaxis in patients who underwent total knee arthroplasty.
Mun Hon LOW ; Seng Jin YEO ; Pak Lin CHIN ; Shi Lu CHIA ; Ngai Nung LO ; Keng Jin TAY
Singapore medical journal 2013;54(10):560-563
INTRODUCTIONThere is considerable controversy regarding the best method to prevent venous thromboembolism. In 2008, the American College of Chest Physicians (ACCP) published specific guidelines recommending the use of ow-molecular-weight heparin or warfarin, and a target international normalised ratio of 2.0-3.0 for a duration of at least 7-10 days, after elective knee arthroplasties. Many orthopaedic surgeons believe that these recommendations are biased toward reducing deep venous thrombosis (DVT), but neglect the implicated possibility of a higher incidence of wound complications. In order to enable an objective evaluation of the fit of the ACCP recommendations to the needs of our local cohort of patients, we aimed to look at the incidence of DVT in our local population.
METHODSThis study was a prospective observational study involving existing local patients in Singapore General Hospital, Singapore, who underwent total knee arthroplasty (TKA) and were on a short course of chemothromboprophylaxis (< 7 days) after the operation. The incidence of DVT in patients was evaluated using DVT imaging 4-6 days after the operation and at one month after the operation.
RESULTSIn our study cohort, the prevalence of DVT during the period between postoperative Days 4 and 6 was 12% (11% were distal DVT and 1% was proximal DVT). Only 9% of the patients had DVT one month after the operation. Using chi-square analysis, we found that there was no significant increase in the number of DVT and pulmonary embolism cases 4-6 days and 1 month after the operation (p > 0.05).
CONCLUSIONContrary to the ACCP guidelines, a short course of chemothromboprophylaxis post TKA, lasting no more than 7 days, is safe and adequate in the low-risk Asian population.
Adult ; Aged ; Aged, 80 and over ; Anticoagulants ; therapeutic use ; Arthroplasty, Replacement, Knee ; adverse effects ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Heparin, Low-Molecular-Weight ; therapeutic use ; Humans ; Incidence ; Male ; Middle Aged ; Osteoarthritis, Knee ; surgery ; Postoperative Complications ; Prognosis ; Prospective Studies ; Singapore ; epidemiology ; Treatment Outcome ; Venous Thrombosis ; epidemiology ; etiology ; prevention & control ; Warfarin ; therapeutic use